{"id":429272,"date":"2010-03-15T10:51:08","date_gmt":"2010-03-15T14:51:08","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=68527"},"modified":"2010-03-15T10:51:08","modified_gmt":"2010-03-15T14:51:08","slug":"forma-to-discover-lymphoma-drugs-in-deal-with-leukemia-lymphoma-society","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/429272","title":{"rendered":"Forma to Discover Lymphoma Drugs in Deal with Leukemia & Lymphoma Society"},"content":{"rendered":"\n
Life Sciences<\/a>, cancer<\/a>, deals<\/a><\/div>\n

\t\tRyan McBride wrote:<\/strong><\/p>\n

Cambridge, MA-based Forma Therapeutics has formed a partnership with the Leukemia & Lymphoma Society of White Plains, NY, to discover drugs for immune cell cancers, according to a press release<\/a>. No financial details were revealed. The partnership will focus on blocking a protein known as “Bcl-6,” which plays a role many lymphomas. Forma has been on a roll on the fund-raising and partnership fronts<\/a>, having revealed more than $50 million in funding last year as well as a drug-discovery deal with Lexington, MA-based Cubist Pharmaceuticals (NASDAQ:CBST<\/a>).<\/p>\n

Comments (2)<\/a> | Reprints<\/a> | Share:  
\n\"Retweet\"\/<\/a>
\n \"Facebook\"\/<\/a>
\n \"Email\"\/<\/a>
\n \"Share\"\/<\/a>\n<\/div>\n

\t \t\t

\n

\n\"\"<\/a>
\n<\/p>\n

<\/img><\/a>
\n<\/img><\/a><\/p>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Life Sciences, cancer, deals Ryan McBride wrote: Cambridge, MA-based Forma Therapeutics has formed a partnership with the Leukemia & Lymphoma Society of White Plains, NY, to discover drugs for immune cell cancers, according to a press release. No financial details were revealed. The partnership will focus on blocking a protein known as “Bcl-6,” which plays […]<\/p>\n","protected":false},"author":2829,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-429272","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/429272","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/2829"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=429272"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/429272\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=429272"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=429272"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=429272"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}